vs
LOUISIANA-PACIFIC CORP（LPX）与Pediatrix Medical Group, Inc.（MD）财务数据对比。点击上方公司名可切换其他公司
LOUISIANA-PACIFIC CORP的季度营收约是Pediatrix Medical Group, Inc.的1.1倍（$566.0M vs $493.8M），Pediatrix Medical Group, Inc.净利率更高（6.8% vs -1.4%，领先8.2%），Pediatrix Medical Group, Inc.同比增速更快（-1.7% vs -16.9%），过去两年Pediatrix Medical Group, Inc.的营收复合增速更高（-0.1% vs -11.6%）
路易斯安那-太平洋公司（简称LP）是美国知名建材制造商，成立于1973年，是美国定向结构刨花板（OSB）生产的开创者，总部现位于田纳西州纳什维尔。作为全球最大的OSB生产商，公司还生产工程木建材产品，通过建材分销商、经销商及家居零售中心向建筑商和业主供货。
Pediatrix Medical Group是美国领先的专科医疗服务提供商，核心业务覆盖母胎医学、新生儿科、儿科心脏病学等儿科亚专科领域，与美国各地医疗机构合作，为女性、新生儿及儿童提供循证专科医疗服务。
LPX vs MD — 直观对比
营收规模更大
LPX
是对方的1.1倍
$493.8M
营收增速更快
MD
高出15.2%
-16.9%
净利率更高
MD
高出8.2%
-1.4%
两年增速更快
MD
近两年复合增速
-11.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $566.0M | $493.8M |
| 净利润 | $-8.0M | $33.7M |
| 毛利率 | 15.0% | — |
| 营业利润率 | -1.6% | 9.9% |
| 净利率 | -1.4% | 6.8% |
| 营收同比 | -16.9% | -1.7% |
| 净利润同比 | -112.9% | 10.5% |
| 每股收益（稀释后） | $-0.12 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LPXMD
| Q4 25 | $566.0M | $493.8M | ||
| Q3 25 | $663.0M | $492.9M | ||
| Q2 25 | $755.0M | $468.8M | ||
| Q1 25 | $724.0M | $458.4M | ||
| Q4 24 | $681.0M | $502.4M | ||
| Q3 24 | $722.0M | $511.2M | ||
| Q2 24 | $814.0M | $504.3M | ||
| Q1 24 | $724.0M | $495.1M |
净利润LPXMD
| Q4 25 | $-8.0M | $33.7M | ||
| Q3 25 | $9.0M | $71.7M | ||
| Q2 25 | $54.0M | $39.3M | ||
| Q1 25 | $91.0M | $20.7M | ||
| Q4 24 | $62.0M | $30.5M | ||
| Q3 24 | $90.0M | $19.4M | ||
| Q2 24 | $160.0M | $-153.0M | ||
| Q1 24 | $108.0M | $4.0M |
毛利率LPXMD
| Q4 25 | 15.0% | — | ||
| Q3 25 | 19.5% | — | ||
| Q2 25 | 23.6% | — | ||
| Q1 25 | 27.2% | — | ||
| Q4 24 | 23.8% | — | ||
| Q3 24 | 26.7% | — | ||
| Q2 24 | 32.3% | — | ||
| Q1 24 | 29.6% | — |
营业利润率LPXMD
| Q4 25 | -1.6% | 9.9% | ||
| Q3 25 | 2.7% | 13.8% | ||
| Q2 25 | 10.6% | 12.8% | ||
| Q1 25 | 16.6% | 7.0% | ||
| Q4 24 | 11.0% | 7.8% | ||
| Q3 24 | 16.1% | 6.6% | ||
| Q2 24 | 23.8% | -31.3% | ||
| Q1 24 | 20.0% | 3.2% |
净利率LPXMD
| Q4 25 | -1.4% | 6.8% | ||
| Q3 25 | 1.4% | 14.5% | ||
| Q2 25 | 7.2% | 8.4% | ||
| Q1 25 | 12.6% | 4.5% | ||
| Q4 24 | 9.1% | 6.1% | ||
| Q3 24 | 12.5% | 3.8% | ||
| Q2 24 | 19.7% | -30.3% | ||
| Q1 24 | 14.9% | 0.8% |
每股收益（稀释后）LPXMD
| Q4 25 | $-0.12 | $0.40 | ||
| Q3 25 | $0.13 | $0.84 | ||
| Q2 25 | $0.77 | $0.46 | ||
| Q1 25 | $1.30 | $0.24 | ||
| Q4 24 | $0.90 | $0.37 | ||
| Q3 24 | $1.28 | $0.23 | ||
| Q2 24 | $2.23 | $-1.84 | ||
| Q1 24 | $1.48 | $0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $292.0M | $375.2M |
| 总债务越低越好 | $348.0M | $570.5M |
| 股东权益账面价值 | $1.7B | $865.9M |
| 总资产 | $2.6B | $2.2B |
| 负债/权益比越低杠杆越低 | 0.20× | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资LPXMD
| Q4 25 | $292.0M | $375.2M | ||
| Q3 25 | $316.0M | $340.1M | ||
| Q2 25 | $333.0M | $224.7M | ||
| Q1 25 | $256.0M | $99.0M | ||
| Q4 24 | $340.0M | $229.9M | ||
| Q3 24 | $346.0M | $103.8M | ||
| Q2 24 | $317.0M | $19.4M | ||
| Q1 24 | $244.0M | $8.0M |
总债务LPXMD
| Q4 25 | $348.0M | $570.5M | ||
| Q3 25 | $348.0M | $577.2M | ||
| Q2 25 | $348.0M | $583.9M | ||
| Q1 25 | $348.0M | $590.5M | ||
| Q4 24 | $348.0M | $597.1M | ||
| Q3 24 | $347.0M | — | ||
| Q2 24 | $347.0M | — | ||
| Q1 24 | $347.0M | — |
股东权益LPXMD
| Q4 25 | $1.7B | $865.9M | ||
| Q3 25 | $1.7B | $890.7M | ||
| Q2 25 | $1.7B | $833.8M | ||
| Q1 25 | $1.7B | $789.2M | ||
| Q4 24 | $1.7B | $764.9M | ||
| Q3 24 | $1.7B | $732.5M | ||
| Q2 24 | $1.7B | $706.5M | ||
| Q1 24 | $1.6B | $856.2M |
总资产LPXMD
| Q4 25 | $2.6B | $2.2B | ||
| Q3 25 | $2.6B | $2.2B | ||
| Q2 25 | $2.7B | $2.1B | ||
| Q1 25 | $2.6B | $2.0B | ||
| Q4 24 | $2.6B | $2.2B | ||
| Q3 24 | $2.6B | $2.1B | ||
| Q2 24 | $2.5B | $2.0B | ||
| Q1 24 | $2.5B | $2.2B |
负债/权益比LPXMD
| Q4 25 | 0.20× | 0.66× | ||
| Q3 25 | 0.20× | 0.65× | ||
| Q2 25 | 0.20× | 0.70× | ||
| Q1 25 | 0.21× | 0.75× | ||
| Q4 24 | 0.21× | 0.78× | ||
| Q3 24 | 0.21× | — | ||
| Q2 24 | 0.21× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $67.0M | $114.1M |
| 自由现金流经营现金流 - 资本支出 | $-8.0M | — |
| 自由现金流率自由现金流/营收 | -1.4% | — |
| 资本支出强度资本支出/营收 | 13.3% | — |
| 现金转化率经营现金流/净利润 | — | 3.39× |
| 过去12个月自由现金流最近4个季度 | $91.0M | — |
8季度趋势，按日历期对齐
经营现金流LPXMD
| Q4 25 | $67.0M | $114.1M | ||
| Q3 25 | $89.0M | $137.3M | ||
| Q2 25 | $162.0M | $137.2M | ||
| Q1 25 | $64.0M | $-117.5M | ||
| Q4 24 | $105.0M | $133.0M | ||
| Q3 24 | $183.0M | $91.8M | ||
| Q2 24 | $212.0M | $107.0M | ||
| Q1 24 | $105.0M | $-125.2M |
自由现金流LPXMD
| Q4 25 | $-8.0M | — | ||
| Q3 25 | $5.0M | — | ||
| Q2 25 | $94.0M | — | ||
| Q1 25 | $0 | — | ||
| Q4 24 | $43.0M | — | ||
| Q3 24 | $139.0M | — | ||
| Q2 24 | $176.0M | — | ||
| Q1 24 | $64.0M | — |
自由现金流率LPXMD
| Q4 25 | -1.4% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 12.5% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 6.3% | — | ||
| Q3 24 | 19.3% | — | ||
| Q2 24 | 21.6% | — | ||
| Q1 24 | 8.8% | — |
资本支出强度LPXMD
| Q4 25 | 13.3% | — | ||
| Q3 25 | 12.7% | — | ||
| Q2 25 | 9.0% | — | ||
| Q1 25 | 8.8% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | 6.1% | — | ||
| Q2 24 | 4.4% | — | ||
| Q1 24 | 5.7% | — |
现金转化率LPXMD
| Q4 25 | — | 3.39× | ||
| Q3 25 | 9.89× | 1.91× | ||
| Q2 25 | 3.00× | 3.49× | ||
| Q1 25 | 0.70× | -5.66× | ||
| Q4 24 | 1.69× | 4.36× | ||
| Q3 24 | 2.03× | 4.72× | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 0.97× | -31.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LPX
| OS Bvalueadd | $472.0M | 83% |
| Other | $84.0M | 15% |
| Otherproducts | $10.0M | 2% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
